Shire gets EU nod to make Replagal in Lexington
This article was originally published in Scrip
Shire has received approval from the EMA for the purification of its Fabry disease enzyme replacement therapy Replagal (agalsidase alfa) at its new facility in Lexington, Massachusetts. The firm says that it will be able to meet current and anticipated additional demand for the product, which was already being purified at its facility in Alewife, Cambridge, Massachusetts.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.